title: Beyond chemotherapy: targeted therapies in ovarian cancer.
abstract: Ovarian cancer is the leading cause of death from gynaecological malignancies in the Western world. Despite the evolution of surgical techniques and meticulously designed chemotherapy regimens, relapse remains almost inevitable in patients with advanced disease. In an age when great advances have been made in understanding the genetics and molecular biology of this heterogeneous disease, it is likely that the introduction of novel targeted therapies will have a major impact on the management of ovarian cancer. Importantly, such strategies might allow selection of treatments based on the molecular characteristics of tumours and bring us closer to an era of personalized medicine.
authors.affiliation: The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK. stan.kaye@rmh.nhs.uk
authors.forename: Timothy A
authors.initials: TA
authors.lastname: Yap
authors.forename: Craig P
authors.initials: CP
authors.lastname: Carden
authors.forename: Stan B
authors.initials: SB
authors.lastname: Kaye
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002352:Carrier Proteins / Q000037:antagonists & inhibitors; D002986:Clinical Trials as Topic; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005260:Female; D058973:Folate Receptors, GPI-Anchored; D006801:Humans; D010051:Ovarian Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D000081082:Phosphoinositide-3 Kinase Inhibitors; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011494:Protein Kinases / Q000187:drug effects; D019009:Proto-Oncogene Proteins c-kit / Q000187:drug effects; D011956:Receptors, Cell Surface / Q000037:antagonists & inhibitors; D017479:Receptors, Platelet-Derived Growth Factor / Q000037:antagonists & inhibitors; D058570:TOR Serine-Threonine Kinases
chemical_list: D020533:Angiogenesis Inhibitors; D002352:Carrier Proteins; D058973:Folate Receptors, GPI-Anchored; D000081082:Phosphoinositide-3 Kinase Inhibitors; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011956:Receptors, Cell Surface; D011494:Protein Kinases; C546842:MTOR protein, human; D066246:ErbB Receptors; D019009:Proto-Oncogene Proteins c-kit; D017479:Receptors, Platelet-Derived Growth Factor; D058570:TOR Serine-Threonine Kinases